TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07840326: A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)

Sponsor: Sundance Biosciences, Inc. · Phase: PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$853,600

Rescue Site Savings

+$582,000

Unlock Full NCT07840326 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07840326 Rescue Dossier →